ResearchRSSToday
A new study found that babies born early who develop a lung condition called bronchopulmonary dysplasia (BPD) often need medications to treat high blood pressure in their lungs (pulmonary hypertension). However, as these children grow into toddlers around age 2, many of them stop needing these medications. This suggests that the lung condition may improve naturally as kids get older.
WHY IT MATTERSIf your child with BPD and pulmonary hypertension is on PH medications, this research suggests their doctor may be able to reduce or stop treatment as they grow, potentially reducing long-term medication burden and side effects.
ResearchRSSYesterday
A large study found that children with Duchenne muscular dystrophy (DMD) who started taking corticosteroids—a type of anti-inflammatory medicine—earlier in life had better muscle strength and movement than children who started the medicine about a year later. This shows that starting treatment as soon as possible after diagnosis helps preserve how well kids can walk, run, and use their muscles.
WHY IT MATTERSIf you have a young child with DMD, this research provides strong evidence to discuss with your doctor about starting corticosteroid treatment immediately after diagnosis rather than waiting, as earlier treatment may significantly slow muscle weakness.
ResearchRSS2 days ago
Scientists discovered that blocking a protein pathway called JNK in the body may help treat spinal muscular atrophy (SMA), a disease that weakens muscles. In mice with severe SMA, blocking this pathway reduced how bad the disease got and helped the mice live longer. This new approach could work by itself or combined with medicines that are already approved for SMA.
WHY IT MATTERSIf this JNK pathway blocking approach moves to human trials, it could offer SMA patients a new treatment option, potentially as a combination therapy with existing approved drugs like nusinersen or onasemnogene abeparvovec.
ResearchRSS2 days ago
Researchers found that a Parkinson's disease medication called Crexont helped patients spend more time feeling better and less time experiencing symptoms when they switched from other levodopa treatments. The study showed improvements in movement control and daily functioning across different patient groups. This is early-stage research being presented at a medical conference.
WHY IT MATTERSIf you take levodopa for Parkinson's and struggle with 'off' periods when symptoms return between doses, Crexont may offer a way to extend your good symptom control time throughout the day.
ResearchRSS2 days ago
Scientists found that haloperidol, a medication normally used to treat psychiatric conditions, may help treat spinal muscular atrophy (SMA) by increasing levels of a protein called SMN that is missing or low in SMA patients. In laboratory tests with mouse cells and human patient cells, haloperidol helped nerve cells survive longer, reduced harmful inflammation, and improved movement. This suggests haloperidol could potentially be used alongside or instead of current SMA treatments.
WHY IT MATTERSIf haloperidol proves effective in human trials, SMA patients could potentially benefit from a medication that already exists and is FDA-approved, potentially offering a faster path to treatment than developing entirely new drugs.
ResearchPUBMED3 days ago
Linear interstitial keratitis (LIK) is a very rare eye condition where a thin line of cloudiness forms in the clear part of the eye (the cornea). This study looked at 6 patients with this condition to better understand what it looks like, how doctors can diagnose it, and what treatments work best. The researchers found that the cloudy line usually appears near the edge of the cornea and can be seen clearly with special eye imaging tools.
WHY IT MATTERSThis is the largest study to date on linear interstitial keratitis, providing eye doctors with new guidance on diagnosis and treatment options for a condition that previously had no agreed-upon management approach.
ResearchCLINICALTRIALSApr 17
Researchers completed a study that collected information about how Canavan disease develops and progresses in children. The study looked at medical records from 67 patients and also gathered new information about their movement abilities and important health milestones. This type of study helps doctors understand the disease better and can guide future treatment development.
WHY IT MATTERSThis completed natural history study provides detailed data on how Canavan disease progresses in children, which is essential for designing future clinical trials and understanding what to expect from the disease.
ResearchBIORXIVApr 17
Scientists created OpenScientist, a new artificial intelligence tool that can help researchers discover medical breakthroughs faster. This AI assistant can read through lots of medical information, analyze data, and put together what it learns — tasks that normally take human scientists a long time. The goal is to speed up finding new treatments and understanding diseases better.
WHY IT MATTERSThis AI tool could help researchers discover new treatments and understand rare diseases more quickly by automating time-consuming research tasks, potentially leading to faster development of therapies for patients with rare conditions.
ResearchBIORXIVApr 17
Scientists are testing a new way to understand how genes cause diseases by combining two different research methods: one that studies genes in large groups of people, and another that looks at individual cells in the lab. This study checks whether both methods give the same answers, which would help researchers trust their findings more and move treatments from the lab to real patients faster.
WHY IT MATTERSIf validated, this approach could accelerate how researchers identify disease-causing genes in rheumatologic conditions, potentially leading to faster development of targeted treatments for patients with autoimmune and inflammatory diseases.
ResearchBIORXIVApr 14
Researchers studied how much money families and the healthcare system spend on KCNT1-related disorders, a rare genetic brain condition that causes severe seizures starting in early childhood. The study used information from both families caring for patients and medical records to understand the true financial costs. This is important because there are currently no approved treatments that can change the course of the disease, so families face lifelong expensive care.
WHY IT MATTERSIf you have a child with KCNT1-related epilepsy, this research documents the financial burden your family faces and provides evidence that could support insurance coverage decisions and funding for new treatments.
ResearchPUBMEDApr 13
This article helps doctors who read medical images understand rare tumors that grow in women's reproductive organs. These tumors are uncommon, affecting fewer than 6 out of every 100,000 people each year, which makes them hard to diagnose and treat. The article explains what these tumors look like on imaging scans and how doctors can better identify them to help plan treatment.
WHY IT MATTERSIf you have been diagnosed with an uncommon gynecological tumor, radiologists who understand these rare conditions are better equipped to provide accurate imaging reports that guide your treatment decisions.
ResearchBIORXIVApr 12
Scientists created animal models (using fish and mice) that mimic DeSanto-Shinawi Syndrome, a rare genetic disorder caused by mutations in the WAC gene. These animal models showed symptoms similar to what patients experience, including developmental delays, intellectual disability, autism-like behaviors, and seizures. This research helps scientists understand how WAC gene mutations cause these symptoms and could lead to better treatments in the future.
WHY IT MATTERSFor the first time, researchers have created animal models that reproduce the key symptoms of DeSanto-Shinawi Syndrome, which could accelerate the discovery of why patients develop autism, seizures, and developmental delays—and potentially identify new treatment targets.
ResearchPUBMEDApr 10
Doctors from around the world created a network called the International Neuroblastoma Risk Group to share information about neuroblastoma, a type of cancer that starts in nerve cells. They combined data from over 25,000 patients to help researchers understand the disease better and develop better treatment plans. This teamwork model shows how rare cancer research can be improved when hospitals and countries work together.
WHY IT MATTERSPatients with neuroblastoma now benefit from standardized treatment approaches and risk classifications developed through this international collaboration, which means more consistent and potentially better care regardless of where they receive treatment.
ResearchPUBMEDApr 5
Researchers looked at studies from 2014 to 2024 about the cost and value of special medicines for rare kidney diseases in poorer countries. They found that there isn't much research on whether these expensive medicines are worth the money in these areas. The study shows that doctors and governments need better information to decide if patients should have access to these treatments.
WHY IT MATTERSIf you have a rare kidney disease in a low- or middle-income country, this research highlights why your access to orphan drugs is limited — there's a major gap in evidence about whether these treatments are affordable and effective in your region.
ResearchUNITERAREApr 3
This is a research study looking for patients and families affected by rare diseases to share their thoughts and values about brain and nerve-related medical decisions. Researchers at St. Jude Children's Research Hospital want to understand what matters most to people living with rare diseases so they can make better ethical decisions in medical research and treatment. The study is now accepting participants and will start in April 2026.
WHY IT MATTERSThis study gives rare disease patients and caregivers a direct voice in shaping how medical ethics and brain-related research decisions are made — your input could influence future treatment guidelines and research practices.
ResearchBIORXIVApr 2
Researchers discovered that mutations in a gene called THAP12 cause a severe type of childhood epilepsy called developmental and epileptic encephalopathy. Two siblings with this condition had two broken copies of the THAP12 gene (one from each parent), which stopped the gene from making enough of its protein. This finding helps explain why some children develop severe seizures early in life and could lead to better diagnosis and treatment options.
WHY IT MATTERSFamilies with children diagnosed with infantile spasms or Lennox-Gastaut syndrome now have a new genetic cause to test for, which could explain their child's condition and guide future treatment decisions.
ResearchPUBMEDApr 1
Scientists are developing a new technology called Digital Twins—computer models that act like virtual copies of individual patients. These virtual copies could help doctors diagnose rare childhood diseases faster and find better treatments by testing ideas on the computer before trying them on real patients. This is especially helpful for rare diseases because there aren't many patients to study, and it's hard to do traditional research on children.
WHY IT MATTERSDigital twins could speed up diagnosis and enable personalized treatment plans for children with rare diseases, potentially reducing the years of diagnostic delay that currently affects most pediatric rare disease patients.
ResearchPUBMEDApr 1
Researchers studied whether the amount of cancer in a patient's body before treatment affects how well two immunotherapy drugs work together. They looked at 722 patients with rare cancers who received nivolumab and ipilimumab (two drugs that help the immune system fight cancer). The study wanted to understand if patients with smaller tumors do better than those with larger tumors when treated with these combination drugs.
WHY IT MATTERSIf baseline tumor size predicts treatment response in rare cancers, doctors could better counsel patients on expected outcomes and identify which patients might benefit most from this dual immunotherapy approach before starting treatment.
ResearchPUBMEDApr 1
Scientists are developing a new way to study rare bone diseases using lab-grown bone tissue called organoids. Instead of only using animal tests or simple cell cultures, researchers can now grow tiny bone structures that act like real bones. This helps them understand why these diseases happen and test new treatments more accurately before trying them in patients.
WHY IT MATTERSFor patients with rare skeletal disorders, bone organoids could speed up the discovery of treatments by allowing researchers to test drugs on disease-specific bone tissue grown from patient cells, potentially leading to personalized medicine approaches.
ResearchPUBMEDApr 1
Doctors are getting better at using a special imaging machine called PET/MR that combines two types of scans to diagnose rare diseases in children. This machine is especially helpful because it takes clearer pictures while using less radiation than older machines, which is important for kids. The machine works well for finding tumors, genetic disorders, and inflammatory diseases, and doctors can use it to check how well treatments are working.
WHY IT MATTERSIf your child has a rare disease requiring imaging, PET/MR technology may reduce their radiation exposure and the number of separate scans needed compared to traditional imaging methods.